Drug Database
HE

Hep A-Vi (ViATIM / ViVAXIM)

✓ Approved

Sanofi S.A · Vaccine · Vaccine

What is Hep A-Vi?

Hep A-Vi is a vaccine developed by Sanofi S.A. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesViATIM, ViVAXIM
CompanySanofi S.A
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

Hep A-Vi is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsTyphoid fever✓ Approved
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

Related Research Articles

PubMedPhysical therapy2026-05-24

Efficacy of Physical Therapy Interventions Delivered With Home Exercise Programs for Pain and Function in Plantar Fasciitis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

Li Zelin Z, He Siyi S, Wu Jiaqi J, Zhu Zhaoying Z et al.

This study aimed to compare the effects of 7 physical therapy interventions delivered with Home Exercise Program (HEP) versus HEP alone on pain and function in plantar fasciitis (PF). Studies were identified through PubMed, Embase, the Cochrane Library, Web of Science, and Scopus from database inception to January 2026. Randomized controlled trials (RCTs) comparing physical therapy interventions delivered with HEP versus HEP alone in individuals with PF were included. A frequentist random-effects network meta-analysis was conducted.Outcomes were assessed at short-term (≤6 weeks), medium-term (6-12 weeks), and long-term (≥12 weeks) follow-up periods. Eight treatment nodes were analyzed: extracorporeal shock wave therapy, ultrasound therapy, manual therapy, taping, low-level laser therapy, orthoses, and dry needling, all delivered with HEP, and HEP alone as the control. Risk of bias was assessed using the Cochrane Risk-of-Bias tool (RoB2), and the certainty of evidence was evaluated with the Confidence in Network Meta-Analysis (CINeMA) framework. Pain and functional outcomes were evaluated using standardized mean differences (SMDs) with 95% confidence intervals (CIs). Twenty-four RCTs (1240 participants) were included. For pain outcomes, dry needling (SMD = -1.26, 95% CI = -2.25 to -0.28), low-level laser therapy (-1.54, -2.82 to -0.27), and manual therapy (-1.02, -1.82 to -0.21), delivered with HEP, resulted in clinically significant improvements in short-term pain (moderate-quality evidence). The pain-relieving effects of dry needling delivered with HEP were sustained in the medium term (-1.14, -1.62 to -0.66; high-quality evidence). For functional outcomes, dry needling (0.66, 0.13 to 1.19) and taping (0.84, 0.27 to 1.40), delivered with HEP, resulted in clinically significant improvements in short-term function (moderate-quality evidence). Additionally, dry needling with HEP sustained significant clinical improvements in medium-term function (1.06, 0.24 to 1.87; moderate-quality evidence). When delivered with HEP, dry needling, low-level laser therapy, and manual therapy provided clinically significant short-term improvements in pain compared to HEP alone, with dry needling and taping improving short-term functional outcomes. Dry needling further sustained its benefits in both pain and function into the medium term.

PMID 42176209
Read full article →
PubMedAngewandte Chemie (International ed. in English)2026-05-24

High-Entropy Polymer Electrode for Fast Rechargeable Batteries.

Hu Yanyao Y, Fan Ling L, Lu Bingan B, Yin Shuang-Feng SF

Polymer electrode materials possess the advantages of sustainability, abundant resources, and structural adjustability, yet suffer from poor rate capability and cycling stability. Herein, we propose a concept of molecular structure entropy for the development of a high-entropy polymer (HEP), wherein molecular structure entropy exerts a significant regulatory effect on the physicochemical and electrochemical performance of the resulting polymer. For sodium-based batteries, the Na||HEP cell delivers a high reversible capacity of 167.7 mAh g-1 at a current density of 1 A g-1, a long cycling stability of 5000 cycles, and a high-rate capability of 111.9 mAh g-1 at a current density of 10 A g-1, outperforming the low-entropy polymer. Moreover, the all-organic battery shows a long stability of 15 000 cycles, corresponding to a continuous running time exceeding 200 days. This work sets a precedent for HEP electrodes and establishes a foundation for their further research.

PMID 42175864
Read full article →
PubMedJournal of hazardous materials2026-05-24

Sulfur vacancy-rich MoS2 nanoflowers as electron shuttles boost Fe(VI) activation for efficient micropollutant degradation.

Wu Lian L, Zhou Xin X, Han Zi-Yi ZY, Mu Hui-Zhi HZ et al.

Ferrate (Fe(VI)) has limited applications due to its slow reaction rate with micropollutants under neutral or alkaline conditions. This study presented sulfur-vacancy-rich nanoflower-structured MoS2 synthesized via a simple hydrothermal method, which effectively activated Fe(VI) to rapidly degrade micropollutants. Almost complete removal (98.4-100%) of various micropollutants (e.g., diclofenac (DCF), trimethoprim (TMP), etc.) was achieved within 5 min after adding a low dose of MoS2 (25 mg/L) to the Fe(VI) system, with the rate constants (kobs) 5.3-27.3 times higher than those of Fe(VI) alone. Probe experiments indicated that MoS2 promoted the generation of more intermediate iron species (Fe(V)/Fe(IV)) from Fe(VI), with Fe(V) accounting for 88.8% of the total contribution. Furthermore, by adjusting the concentration of sulfur vacancies (Sv) in MoS2, a relationship between sulfur vacancy abundance and degradation efficiency was established, providing the evidence for the critical role of sulfur vacancies in the activation of Fe(VI). Sv-rich MoS2 served as key electron-shuttling, facilitating the adsorption of Fe(VI) and accelerating electron transfer processes to promote Fe(V)/Fe(IV) generation. The MoS2/Fe(VI) system exhibited outstanding performance across a wide pH range and demonstrated strong resistance to common aquatic components (Cl-, SO42-, etc.). Remarkably, increasing the concentration of humic acid (HA) from 0 to 5 mg/L led to a near-complete degradation of DCF within 2 min, accompanied by a 3.9-fold increase in the kobs value. This phenomenon can be attributed to the electron-shuttling role of HA that synergistically enhanced interfacial electron transfer. Practical application results validated that this system could achieve excellent DCF removal efficiency (96.5-97.9%) in various real water. This work provides fundamental insight into the intrinsic mechanism of defect-engineered MoS2 activating Fe(VI), offering a sustainable and efficient strategy for water purification.

PMID 42176625
Read full article →
PubMedJournal of pharmaceutical and biomedical analysis2026-05-24

Analytical quality by design-based development and validation of a robust impurity analysis method for albumin-bound paclitaxel nanoparticles.

Jeong Hye H, Gil Myung-Chul MC, Cho Young Ho YH, Lee Gye Won GW

Analytical Quality by Design (AQbD) was applied to develop a robust impurity (IMP) analysis method for albumin-bound paclitaxel nanoparticles (Nab-PTX). Preliminary studies revealed that the USP method could induce epimerization, increasing IMP VI (7-epi-paclitaxel) formation. Risk assessment (Ishikawa/FMEA) identified four critical method parameters: flow rate, acetonitrile ratio (ACN), column temperature, and formic acid (FA) content. A 27-run Box-Behnken design (BBD) and response surface modeling (R² = 0.8688-0.9950) revealed complex nonlinear relationships. Specifically, FA content suppressed the dissociation of carboxylic acid groups in early-eluting impurities, significantly improving peak symmetry. To overcome standard software limits, a multidimensional Method Operable Design Region (MODR) was constructed using Monte Carlo simulation (n = 50,000) with a custom Python-based script. Optimal conditions (1.1 mL/min, 40.5% ACN, 25 °C, 0.025% FA) were identified via desirability function (D=0.9589). Experimental verification showed high predictive accuracy (Bias -1.4% to +1.0%). The method was validated per ICH Q2(R1) guidelines, showing excellent linearity (R2≥0.9985), accuracy (87.8-106.2%), and precision (RSD≤0.59%). Notably, acidified sample preparation reduced method-induced IMP VI formation by > 75%, preventing false-positives. This study provides a systematic AQbD framework with computational integration for protein-bound nanomedicines, ensuring superior resolution and 33% faster analysis than compendial methods.

PMID 42176526
Read full article →
PubMedApplied microbiology and biotechnology2026-05-24

Neisseria subflava Type 6 Secretion System competition with bacterial and fungal species.

Calder Alan A, Snyder Lori A S LAS

The aim of this study was to assess whether a Type VI Secretion System (T6SS) present in the commensal, non-pathogenic Neisseria subflava strain KU1003-01 plays a role in competition between these bacteria and other commensal and pathogenic Gram-negative microorganisms and the yeast Candida albicans. Using an overlap extension PCR strategy, the core T6SS gene encoding membrane protein TssM was knocked out for N. subflava strain KU1003-01. Co-culture competition assays were conducted with either the N. subflava or N. subflava tssM knock-out strains as the attackers and N. gonorrhoeae strain NCCP11945, N. subflava strain KU1003-02, or C. albicans strain 3153 as the targets. There was a significant difference in recoverable target cell CFUs observed following co-culture with the T6SS knock-out strain in comparison to the parent strain. TssM has been identified as critical to T6SS function for a number of species, and our findings indicate that the T6SS in N. subflava contributes to competition with these other species. KEY POINTS: • Neisseria subflava Type 6 Secretion System is functional • Neisseria subflava attacks other microbes of the same niche • Neisseria subflava is competent for transformation.

PMID 42176003
Read full article →
PubMedActa cytologica2026-05-24

Real-word Impact of the 2023 Bethesda System on Thyroid FNA Category Distribution: A Multi-phase Longitudinal Study From Algeria.

Yahia Cherif Abderrahmane A, Boudouaya Manel M

The third edition of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC, 2023) introduced refinements in the criteria for indeterminate thyroid lesions. Observed temporal shifts in cytologic categories may reflect both classification changes and evolving technical and interpretive practices. This study evaluated the relative contributions of these factors in a real-world hospital setting. We conducted a retrospective study of 731 ultrasound-guided thyroid fine-needle aspiration (FNA) specimens at a public referral center in western Algeria across four periods: 2017, 2021, 2024, and 2025. Cases from 2017 and 2021 were reported using TBSRTC 2017, while 2024-2025 cases used TBSRTC 2023. Category distributions were compared using chi-square and two-proportion z-tests (p < 0.05). Overall category distribution differed significantly over time (χ² = 61.0, p < 0.0001). Non-diagnostic (Category I) rates declined from 20.5% in 2017 to 7.8% in 2021 (p < 0.001), reflecting technical improvements, and remained stable thereafter (11.7-12.3%). AUS/FLUS (Category III) rates were stable (4.9-7.1%; p > 0.3). Category IV (FN/SFN) transiently increased in 2021 (20.4%) before stabilizing post-2023 implementation (3.1-5.1%; p < 0.0001 for 2021 vs 2024). Categories V-VI remained consistently low (≤4.9% and ≤0.4%, respectively) without evidence of systematic under-calling. Temporal variations in thyroid cytology reflected the combined effects of technical maturation, institutional adaptation, and classification updates rather than TBSRTC 2023 alone. Multi-phase longitudinal analyses are critical to separate these influences when evaluating revised reporting systems, particularly in resource-limited settings.

PMID 42176288
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Hep A-Vi